Selective delipidation of plasma HDL enhances reverse cholesterol transport in vivo

Journal of Lipid Research

Volumn 50, Issue 5, 2009, Pages 894-907

  Sacks, Frank M ^a,c   Rudel, Lawrence L ^b   Conner, Adam ^c   Akeefe, Hassibullah ^c   Kostner, Gerhard ^d   Baki, Talal ^b   Rothblat, George ^e   de la Llera Moya, Margarita ^e   Asztalos, Bela ^f   Perlman, Timothy ^c   Zheng, Chunyu ^a,c   Alaupovic, Petar ^g   Maltais, Jo Ann B ^c   Brewer, H Bryan ^c,h  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b WAKE FOREST UNIVERSITY HEALTH SCIENCES   (United States)

^c Lipid Sciences Inc   (United States)

^d MEDICAL UNIVERSITY OF GRAZ   (Austria)

^e CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^f TUFTS UNIVERSITY   (United States)

^g OKLAHOMA MEDICAL RESEARCH FOUNDATION   (United States)

^h MEDSTAR RESEARCH INSTITUTE   (United States)

Author keywords

ABCA1; Apolipoprotein A I; Kinetics; Lipoproteins; Nonhuman primates; Pre 1; SRB1

Indexed keywords

ABC TRANSPORTER A1; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN; ABC TRANSPORTER; APOLIPOPROTEIN A1; LOW DENSITY LIPOPROTEIN; SCARB1 PROTEIN, HUMAN; SCAVENGER RECEPTOR B;

ANIMAL CELL; ANIMAL EXPERIMENT; AORTA ATHEROSCLEROSIS; ARTICLE; CHOLESTEROL TRANSPORT; CONTROLLED STUDY; FAT INTAKE; HUMAN; IN VIVO STUDY; INTRAVASCULAR ULTRASOUND; LIPID ANALYSIS; LIPOPROTEIN BLOOD LEVEL; MONOCYTE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; ANIMAL; AORTA; ATHEROSCLEROSIS; BLOOD; CELL LINE; CERCOPITHECUS; CHEMISTRY; LIPID METABOLISM; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; TRANSPORT AT THE CELLULAR LEVEL;

ANIMALS; AORTA; APOLIPOPROTEIN A-I; ATHEROSCLEROSIS; ATP-BINDING CASSETTE TRANSPORTERS; BIOLOGICAL TRANSPORT; CELL LINE; CERCOPITHECUS AETHIOPS; CHOLESTEROL; HUMANS; LIPID METABOLISM; LIPOPROTEINS, HDL; LIPOPROTEINS, LDL; MICE; SCAVENGER RECEPTORS, CLASS B;

EID: 67649675003     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.M800622-JLR200     Document Type: Article

References (49)

1. Barr, D. P., E. M. Russ, and H. A. Eder. 1951. Protein-lipid relationships in human plasma. II. In atherosclerosis and related conditions. Am. J. Med. 11: 480-493.
2. Gofman, J. W., W. Young, and R. Tandy. 1966. Ischemic heart disease, Atherosclerosis, and longevity. Circulation. 34: 679-697.
3. Miller, G. J., and N. E. Miller. 1975. Plasma-high-density-lipoprotein concentration and development of ischaemic heart-disease. Lancet. 1: 16-19.
4. Gordon, D. J., J. L. Probstfield, R. J. Garrison, J. D. Neaton, W. P. Castelli, J. D. Knoke, D. R. Jacobs, S. Bangdiwala, and H. A. Tyroler. 1989. High-density lipoprotein cholesterol and cardiovascular disease: four prospective American studies. Circulation. 79: 8-15.
5. Sanossian, N., J. L. Saver, M. Navab, and B. Ovbiagele. 2007. High density lipoprotein cholesterol. An emerging target for stroke treatment. Stroke. 38: 1104-1109.
6. Sacks, F. M., A. M. Tonkin, T. Craven, M. A. Pfeffer, J. Shepherd, A. Keech, C. D. Furberg, and E. Braunwald. 2002. Coronary heart disease in patients with low LDL cholesterol: benefit of pravastatin in diabetics and enhanced role of HDL-cholesterol and triglycerides as risk factors. Circulation. 105: 1424-1428.
7. Cholesterol Treatment Trialists' Collaborators. 2005. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins. Lancet. 366: 1267-1278.
8. Barter, P., A. M. Gotto, J. C. Larosa, J. Maroni, M. Szarek, S. M. Grundy, J. J. Kastelein, V. Bittner, and J. C. Fruchart. 2007. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N. Engl. J. Med. 357: 1301-1310.
9. Brewer, H. B., Jr. 2004. Increasing HDL cholesterol levels. N. Engl. J. Med. 350: 1491-1494.
10. Rader, D. J. 2006. Molecular regulation of HDL metabolism and function: implications for novel therapies. J. Clin. Invest. 116: 3090-30100.
11. Assmann, G., A. Von Eckardstein, and H. B. Brewer. 1995. Familial high density lipoprotein deficiency: Tangier disease. In The Metabolic and Molecular Bases of Inherited Disease. C. R. Scriver, A. L. Beaudet, W. S. Sly, D. Valle, editors. McGraw-Hill, New York, NY. 2053-2072.
12. Serfaty-Lacrosniere, C., F. Civeira, A. Lanzberg, P. Isaia, J. Berg, E. D. Janus, M. P. Smith, P. H. Pritchard, J. Frohlich, R. S. Lees, et al. 1994. Homozygous Tangier disease and cardiovascular disease. Atherosclerosis. 107: 85-98.
13. Brunham, L. R., R. R. Singaraja, and M. R. Hayden. 2006. Variations on a gene: rare and common variants in ABCA1 and their impact on HDL cholesterol levels and atherosclerosis. Annu. Rev. Nutr. 26: 105-129.
14. Singaraja, R. R., C. Fievet, G. Castro, E. R. James, N. Hennuyer, S. M. Clee, N. Bissada, J. C. Choy, J. C. Fruchart, B. M. McManus, et al. 2002. Increased ABCA1 activity protects against atherosclerosis. J. Clin. Invest. 110: 35-42.
15. Joyce, C. W., M. J. Amar, G. Lambert, B. L. Vaisman, B. Paigen, J. Najib-Fruchart, R. F. Hoyt, Jr., E. D. Neufeld, A. T. Remaley, D. S. Fredrickson, et al. 2002. The ATP binding cassette transporter A1 (ABCA1) modulates the development of aortic atherosclerosis in C57BL/6 and apoE-knockout mice. Proc. Natl. Acad. Sci. USA. 99: 407-412.
16. Asztalos, B. F., E. J. Schaefer, K. V. Horvath, S. Yamashita, M. Miller, G. Franceschini, and L. Calabresi. 2007. Role of LCAT in HDL remodeling: investigation of LCAT deficiency states. J. Lipid Res. 48: 592-599.
17. Yokoyama, S. 2006. Assembly of high density lipoproteins. Arterioscler. Thromb. Vasc. Biol. 26: 20-27.
18. Curtiss, L. K., D. T. Valenta, N. J. Hime, and K. A. Rye. 2006. What is so special about apolipoprotein A-I in reverse cholesterol transport? Arterioscler. Thromb. Vasc. Biol. 26: 12-19.
19. Asztalos, B. F., M. de la Llera-Moya, G. E. Dallal, K. V. Horvath, E. J. Schaefer, and G. H. Rothblat. 2005. Differential effects of HDL sub-populations on cellular ABCA1 and SRB-1 mediated cholesterol efflux. J. Lipid Res. 46: 2246-2253.
20. Kunitake, S. T., K. J. La Sala, and J. P. Kane. 1985. Apolipoprotein A-I-containing lipoproteins with pre-beta electrophoretic mobility. J. Lipid Res. 26: 549-555.
21. Rye, K. A., and P. J. Barter. 2004. Formation and metabolism of prebeta-migrating, lipid-poor apolipoprotein A-I. Arterioscler. Thromb. Vasc. Biol. 24: 421-428.
22. Rothblat, G. H., M. de la Llera-Moya, V. Atger, G. Kellner-Weibel, D. L. Williams, and M. C. Phillips. 1999. Cell cholesterol efflux: integration of old and new observations provides new insights. J. Lipid Res. 40: 781-796.
23. Wang, N., D. Lan, W. Chen, F. Matsuura, and A. R. Tall. 2004. ATP-binding cassette transporters G1 and G4 mediate cellular cholesterol efflux to high-density lipoproteins. Proc. Natl. Acad. Sci. USA. 101: 9774-9779.
24. Kennedy, M. A., G. C. Barrera, K. Nakamura, A. Baldan, P. Tarr, M. C. Fishbein, J. Frank, O. L. Francone, and P. A. Edwards. 2005. ABCG1 has a critical role in mediating cholesterol efflux to HDL and preventing cellular lipid accumulation. Cell Metab. 1: 121-131.
25. Gelissen, I. C., M. Harris, K. A. Rye, C. Quinn, A. J. Brown, M. Kockx, S. Cartland, M. Packianathan, L. Kritharides, and W. Jessup. 2006. ABCA1 and ABCG1 synergize to mediate cholesterol export to apoA-I. Arterioscler. Thromb. Vasc. Biol. 26: 534-540.
26. Ouguerram, K., M. Krempf, C. Maugeais, P. Maugere, D. Darmaun, and T. Magot. 2002. A new labeling approach using stable isotopes to study in vivo plasma cholesterol metabolism in humans. Metabolism. 51: 5-11.
27. Schwartz, C. C., J. M. VandenBroek, and P. S. Cooper. 2004. Lipoprotein cholesteryl ester production, transfer, and output in vivo in humans. J. Lipid Res. 45: 1594-1607.
28. Eriksson, M., L. A. Carlson, T. A. Miettinen, and B. Angelin. 1999. Stimulation of fecal steroid excretion after infusion of recombinant proapolipoprotein A-I. Potential reverse cholesterol transport in humans. Circulation. 100: 594-598.
29. Milano infusion into rabbit carotid artery rapidly removes lipid from fatty streaks. Circ. Res. 90: 974-980.
30. Badimon, J. J., L. Badimon, and V. Fuster. 1990. Regression of atherosclerotic lesions by high density lipoprotein plasma fraction in the cholesterol-fed rabbit. J. Clin. Invest. 85: 1234-1241.
31. Shah, P. K., J. Yano, O. Reyes, K. Y. Chyu, S. Kaul, C. L. Bisgaier, S. Drake, and B. Cercek. 2001. High-dose recombinant apolipoprotein A-I Milano mobilizes tissue cholesterol and rapidly reduces plaque lipid and macrophage content in apolipoprotein E-deficient mice - Potential implications for acute plaque stabilization. Circulation. 103: 3047-3050.
32. Ameli, S., A. Hultgardh-Nilsson, B. Cercek, P. K. Shah, J. S. Forrester, H. Ageland, and J. Nilsson. 1994. Recombinant apolipoprotein A-I Milano reduces intimal thickening after balloon injury in hypercholesterolemic rabbits. Circulation. 90: 1935-1941.
33. Nissen, S. E., T. Tsunoda, E. M. Tuzcu, P. Schoenhagen, C. J. Cooper, M. Yasin, G. M. Eaton, M. A. Lauer, W. S. Sheldon, C. L. Grines, et al. 2003. Effect of recombinant apoA-I milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. JAMA. 290: 2292-2300.
34. Alaupovic, P. 1996. Significance of apolipoproteins for structure, function, and classification of plasma lipoproteins. Methods Enzymol. 263: 32-60.
35. Ogawa, Y., and C. J. Fielding. 1985. Assay of cholesteryl ester transfer activity and purification of a cholesteryl ester transfer protein. Methods Enzymol. 111: 274-285.
36. Fielding, C. J., R. J. Havel, K. M. Todd, K. E. Yeo, M. C. Schloetter, V. Weinberg, and P. H. Frost. 1995. Effects of dietary cholesterol and fat saturation on plasma lipoproteins in an ethically diverse population of healthy young men. J. Clin. Invest. 95: 611-618.
37. de la Llera Moya, M., V. Atger, J. L. Paul, N. Fournier, N. Moatti, P. Giral, K. E. Friday, and G. Rothblat. 1994. A cell culture system for screening human serum for ability to Promote cellular cholesterol efflux. Relations between serum components and efflux, esterification, and transfer. Arterioscler. Thromb. 14: 1056-1065.
38. Koritnik, D. L., and L. L. Rudel. 1983. Measurement of apolipoprotein A-1 concentration in nonhuman primate serum by enzymelinked immunosorbent assay (ELISA). J. Lipid Res. 24: 1639-1645.
39. Colvin, P. L., E. Moriguchi, P. H. Barrett, J. S. Parks, and L. L. Rudel. 1999. Small HDL particles containing two apoA-I molecules are precursors in vivo to medium and large HDL particles containing three and four apoA-I molecules in nonhuman primates. J. Lipid Res. 40: 1782-1792.
40. Mintz, G. S., S. E. Nissen, W. D. Anderson, S. R. Bailey, R. Erbel, P. J. Fitzgerald, F. J. Pinto, K. Rosenfield, R. J. Siegel, E. M. Tuzcu, et al. 2001. American College of Cardiology Clinical Expert Consensus Document on Standards for Acquisition, Measurement and Reporting of Intravascular Ultrasound Studies (IVUS). A report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents. J. Am. Coll. Cardiol. 37: 1478-1492.
41. Jolley, C. D., L. A. Woollett, S. D. Turley, and J. M. Dietschy. 1998. Centripetal cholesterol flux to the liver is dictated by events in the peripheral organs and not by the plasma high density lipoprotein or apolipoprotein A-I concentration. J. Lipid Res. 39: 2143-2149.
42. Neufeld, E. B., J. A. Stonik, S. J. Demosky, C. L. Knapper, C. A. Combs, A. Cooney, M. Comly, N. Dwyer, J. Blanchette-Mackie, A. T. Remaley, et al. 2004. The ABCA1 transporter modulates late endocytic trafficking: insights from the correction of the genetic defect in Tangier disease. J. Biol. Chem. 279: 15571-15578.
43. Gylling, H., G. L. Vega, and S. M. Grundy. 1992. Physiologic mechanisms for reduced apolipoprotein A-I concentration associated with low levels of high density lipoprotein-cholesterol levels in patients with normal plasma lipids. J. Lipid Res. 33: 1527-1539.
44. Nanjee, M. N., J. R. Crouse, J. M. King, R. Hovorka, S. E. Rees, E. R. Carson, J. J. Morgenthaler, P. Lerch, and N. E. Miller. 1996. Effects of intravenous infusion of lipid-free apo A-I in humans. Arterioscler. Thromb. Vasc. Biol. 16: 1203-1214.
45. Chetiveaux, M., F. Lalanne, G. Lambert, Y. Zair, K. Ouguerram, and M. Krempf. 2006. Kinetics of preβ1 HDL and αHDL in type II diabetic patients. Eur. J. Clin. Invest. 36: 29-34.
46. Paterno, R. R., A. Postiglione, A. Hubsch, I. Andresen, and M. G. Lang. 2004. Reconstituted high-density lipoprotein exhibits neuroprotection in two rat models of stroke. Cerebrovasc. Dis. 17: 204-211.
47. Calabresi, L., G. Rossoni, M. Gomaraschi, F. Sisto, F. Berti, and G. Franceschini. 2003. High-density lipoproteins protect isolated rat hearts from ischemia-reperfusion injury by reducing cardiac tumor necrosis factor-alpha content and enhancing prostaglandin release. Circ. Res. 92: 330-337.
48. Marchesi, M., E. A. Booth, T. Davis, C. L. Bisgaier, and B. R. Lucchesi. 2004. Apolipoprotein A-IMilano and 1-Palmitoyl-2-oleoyl phosphatidylcholine complex (ETC-216) protects the in vivo rabbit heart from regional ischemia-reperfusion injury. J. Pharmacol. Exp. Ther. 311: 1023-1031.
49. Kaul, S., V. Rukshin, R. Santos, B. Azarbal, C. L. Bisgaier, and J. Johansson. 2003. Intramural delivery of recombinant apolipoprotein A-IMilano/phospholipid complex (ETC-216) inhibits in-stent stenosis in porcine coronary arteries. Circulation. 107: 2551-2554.